Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hayley Dysert"'
Autor:
Hayley Dysert, Jason Valent, Nathaniel Rosko, Robert M. Dean, Lisa Rybicki, Christy J. Samaras, Beth Faiman, Rajshekhar Chakraborty, Megan O. Nakashima, Faiz Anwer
Publikováno v:
British Journal of Haematology. 189:1074-1082
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma (MM) is lacking in the current literature. We evaluated 258 patients with relapsed MM, diagnosed from 2008 to 2015, to investigate the prognostic impact of deep immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95485c3776250b39adfcd8492ec1c770
https://doi.org/10.1111/bjh.16488
https://doi.org/10.1111/bjh.16488
Autor:
Janice Reed, Kristen Schlueter, Lisa Rybicki, M. A. Karam, Nathaniel Rosko, Jason Valent, Matt Kalaycio, Rajshekhar Chakraborty, Hayley Dysert, Diana Basali
Publikováno v:
British Journal of Haematology. 189:1136-1140
The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, is a promising agent, especially in patients harbouring t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82027100b3e0d10cc1cfaa35e94d21d5
https://doi.org/10.1111/bjh.16454
https://doi.org/10.1111/bjh.16454
Autor:
Gabriel K. Habermehl, Huimin Liu, Xiaofeng Jiang, Fjorela Xhyliu, Jason Valent, Eric D. Hsi, Nikhil C. Munshi, Juraj Bodo, Wenjun Li, Jianhong Lin, Sarah L. Ondrejka, Kenneth C. Anderson, Geyou Ao, Yi Hu, Hayley Dysert, Benjamin E. Russell, Marcia Chappell, Jaroslaw P. Maciejewski, Chen Li, Qing Yi, Jianjun Zhao, Chuanfeng Fang
Publikováno v:
Cancer Res
Multiple myeloma is an incurable refractory hematologic malignancy arising from plasma cells in the bone marrow. Here we investigated miR-26a function in multiple myeloma and tested single-wall carbon nanotube delivery of miR-26a in vitro and in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e8bf9ba287aaaaeae5597dcd802485
https://pubmed.ncbi.nlm.nih.gov/32193289
https://pubmed.ncbi.nlm.nih.gov/32193289
Autor:
Jianjun Zhao, Yi Hu, Huimin Liu, Chuanfeng Fang, Chen Li, Fjorela Xhyliu, Juraj Bodo, Hayley Dysert, Gabriel Habermehl, Benjamin Russell, Wenjun Li, Marcia Chappell, Xiaofeng Jiang, Sarah Ondrejka, Eric Hsi, Jaroslaw P Maciejewski, Qing Yi, Kenneth C Anderson, Nikhil C Munshi, Geyou Ao, Jason Valent, Jianhong Lin
Publikováno v:
The Journal of Immunology. 204:91.10-91.10
Daratumumab is the first CD38 antibody drug for MM patients therapy. CD38 remains at a low level during daratumumab treatment and shows a sustained high quality response. In daratumumab resistant MM cells, CD38 expression was found either totally res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bd02d9f6023e71162e05e35495478aa
https://doi.org/10.4049/jimmunol.204.supp.91.10
https://doi.org/10.4049/jimmunol.204.supp.91.10
Autor:
Janice Reed, Hayley Dysert, Kristen Schlueter, Matt Kalaycio, Jason Valent, Diana Basali, Kimberly Hamilton, Lisa Rybicki, Rajshekhar Chakraborty, Beth Faiman, Mary Ann Karam, Nathaniel Rosko
Publikováno v:
Blood. 134:5566-5566
Background: Venetoclax is an orally bioavailable inhibitor of the anti-apoptotic protein Bcl-2. In Multiple Myeloma [MM] characterized by t[11;14], it is particularly effective with a single-agent response rate of 40%. However, there have been recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9ba9b06d0c2231d5f198cc8b29a9c1d
https://doi.org/10.1182/blood-2019-129002
https://doi.org/10.1182/blood-2019-129002